SCHEMBL14072437

SCHEMBL14072437

O=C(O)c1nc(=O)[nH]c2ccccc12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 4/20 0.68
KDM4E B2RXH2 7/20 0.57
ALDH1A1 P00352 5/20 0.57
HPGD P15428 4/20 0.57
HSD17B10 Q99714 2/20 0.57
TSHR P16473 1/20 0.57
DYRK1A Q13627 1/20 0.54
TDP1 Q9NUW8 1/20 0.50
APP P05067 2/20 0.49
KMT2A Q03164 2/20 0.49
GLA P06280 2/20 0.49
GAA P10253 2/20 0.49
MEN1 O00255 1/20 0.49
GRIN2D O15399 1/20 0.49
GRIN3B O60391 1/20 0.49
CYP1A2 P05177 1/20 0.49
MAPK1 P28482 1/20 0.49
CYP2C19 P33261 1/20 0.49
AHR P35869 1/20 0.49
CHRNA7 P36544 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29033598 0.85 ADORA3 (0.62) ADORA3KDM4EALDH1A1HPGDHSD17B10
SCHEMBL17753301 0.84 ADORA3 (0.61) ADORA3KDM4EALDH1A1HPGDHSD17B10
SCHEMBL17753303 0.84 ADORA3 (0.61) ADORA3KDM4EALDH1A1HPGDHSD17B10
SCHEMBL13995844 0.84 ADORA3 (0.61) ADORA3KDM4EALDH1A1HPGDHSD17B10
SCHEMBL8198639 0.84 ADORA3 (0.61) ADORA3KDM4EALDH1A1HPGDHSD17B10
SCHEMBL11487364 0.81 ADORA3 (0.58) ADORA3KDM4EALDH1A1HPGDHSD17B10
SCHEMBL31060760 0.81 ADORA3 (1.00) ADORA3KDM4EALDH1A1HPGDHSD17B10
SCHEMBL7417909 0.80 ADORA3 (0.57) ADORA3KDM4EALDH1A1HPGDHSD17B10
SCHEMBL30725575 0.80 ADORA3 (0.57) ADORA3KDM4EALDH1A1HPGDHSD17B10
SCHEMBL7423796 0.78 ADORA3 (0.55) ADORA3KDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105601621-B Nitrogen-containing polycyclic compound and organic electroluminescent device using the same 株式会社LG化学 2019-05-28 CN disclosed
US-9698358-B2 Nitrogen-containing polycyclic compound and organic electroluminescent device using the same LG CHEM, LTD. (KR) 2017-07-04 US disclosed
US-9698358-B2 Nitrogen-containing polycyclic compound and organic electroluminescent device using the same LG CHEM, LTD. (KR) 2017-07-04 US disclosed
US-9698358-B2 Nitrogen-containing polycyclic compound and organic electroluminescent device using the same LG CHEM, LTD. (KR) 2017-07-04 US disclosed
CN-105601621-A Nitrogen-containing polycyclic compound and organic electroluminescent device using the same LG CHEMICAL LTD 2016-05-25 CN disclosed
US-20160141518-A1 NITROGEN-CONTAINING POLYCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME LG CHEM, LTD. (KR) 2016-05-19 US disclosed
US-20160141518-A1 NITROGEN-CONTAINING POLYCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME LG CHEM, LTD. (KR) 2016-05-19 US disclosed
US-20160141518-A1 NITROGEN-CONTAINING POLYCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME LG CHEM, LTD. (KR) 2016-05-19 US disclosed
WO-2008109179-A1 METALLOPROTEASE INHIBITORS CONTAINING A SQUARAMIDE MOIETY ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2008-09-12 WO disclosed
US-20080221093-A1 Metalloprotease inhibitors containing a heterocyclic moiety ALANTOS PHARMACEUTICALS HOLDING, INC. 2008-09-11 US disclosed
US-20080221093-A1 Metalloprotease inhibitors containing a heterocyclic moiety ALANTOS PHARMACEUTICALS HOLDING, INC. 2008-09-11 US disclosed
US-20080221094-A1 Metalloprotease inhibitors containing a squaramide moiety ALANTOS PHARMACEUTICALS HOLDING, INC. 2008-09-11 US disclosed
US-20080221094-A1 Metalloprotease inhibitors containing a squaramide moiety ALANTOS PHARMACEUTICALS HOLDING, INC. 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221093-A1 Metalloprotease inhibitors containing a heterocyclic moiety MMP12, MMP13, MMP25 ADORA3 3364/4885KDM4E 693/4885ALDH1A1 714/4885
US-20080221094-A1 Metalloprotease inhibitors containing a squaramide moiety MMP13, MMP14, MMP11 ADORA3 2726/4885KDM4E 686/4885ALDH1A1 1641/4885
US-20160141518-A1 NITROGEN-CONTAINING POLYCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME NCL, ODC1, PNMT ADORA3 3413/4885KDM4E 1318/4885ALDH1A1 3323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.